# Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy

> **NCT01280929** · PHASE2 · COMPLETED · sponsor: **José Cunha-Vaz** · enrollment: 54 (actual)

## Conditions studied

- High Risk Proliferative Diabetic Retinopathy

## Interventions

- **PROCEDURE:** Panretinal Photocoagulation (PRP)
- **DRUG:** Intravitreous injection of ranibizumab

## Key facts

- **NCT ID:** NCT01280929
- **Lead sponsor:** José Cunha-Vaz
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280929, "Prospective, Randomized, Multicenter, Open Label, Phase II Study to Access Efficacy and Safety of Lucentis® Monotherapy Compared With Lucentis® Plus Panretinal Photocoagulation (PRP) and PRP in the Treatment of Patients With High Risk Proliferative Diabetic Retinopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01280929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*